Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
26 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2024
Gulliver Biomed from Gent, company number BE0692527837, closed financial year 2024 with a result of € 53,918 after tax. For that financial year Gulliver Biomed recorded a gross margin of € 72,495 and equity of € 74,753. Compared with financial year 2023, the result moved from € -11,437 to € 53,918. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2025.
€ 74,753
▲ 259% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 53,918
▲ still € 11,437 loss in 2023
Profit after tax over the fiscal year.
€ 86,482
▲ € 85,830 vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € 56,153.
People and assets in 2024
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 24,232
▼ 28% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
€ 11,719
▼ 39% vs 2023
€ 7,748 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 3,740
▲ 3% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 17,065
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 9,756 | € 34,471 | € 517 | € 72,495 | ▲ € 71,978 |
| Profit after taxes | € 6,233 | € 21,788 | € -11,437 | € 53,918 | ▲ € 65,356 |
| Equity | € 51,084 | € 78,272 | € 20,834 | € 74,753 | ▲ 259% |
| Total debts | € 11,224 | € 48,705 | € 84,144 | € 41,813 | ▼ 50% |
| Cash | € 48,623 | € 67,244 | € 652 | € 86,482 | ▲ € 85,830 |
| Retained profit | € 38,684 | € 59,672 | € 2,234 | € 56,153 | ▲ € 53,918 |
| Dividend | € 0 | € 800 | € 46,000 | € 0 | ▼ 100% |
| Bank debt | € 0 | € 26,464 | € 19,214 | € 11,719 | ▼ 39% |
| Balance sheet total | € 62,308 | € 126,977 | € 104,978 | € 116,566 | ▲ 11% |
Key figures of Gulliver Biomed, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to Gulliver Biomed?
What happened at Gulliver Biomed in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 53,918. filed late Source: NBB ↗
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 6,233 profit in 2021 to € 53,918 profit in 2024.
Paid € 16,885 in corporate taxes since 2021.
Best year ever: 2024, with € 53,918 profit.
Paid out € 46,800 in dividends to the owners in total.
A new publication or filing at Gulliver Biomed? We notify you, reason included.
Follow Gulliver BiomedDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Gulliver Biomed is Jan Christiaan Gettemans.
Directors
According to the 2024 annual accounts
Jan Christiaan Gettemans
Director
Establishments
Establishment units
Physical locations of this company
Technologiepark-Zwijnaarde 82
9052 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 26 companies are registered at this address.
All companies at this address →CONTREL EUROPE
€ 250,724 gross margin · 2025
INCUBATIE- EN INNOVATIECENTRUM UNIVERSITEIT
€ 1.4 million gross margin · 2025
VP VENTURES
€ -1,670 gross margin · 2025
SENSNET
Inbiose
€ 6.3 million revenue · 2025
+21 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0692.527.837
- VAT number
- BE 0692.527.837
- Registered office
- Technologiepark-Zwijnaarde 82, 9052 Gent
- Names & denominations
- Gulliver Biomed
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 14 March 2018
- Peppol
- Active · Active since 4 Feb 2026
- Activities · NACE
Overige technische testen en toetsen